Transplant in the Elderly AML Patient

The authors concluded that there was no observed transplant benefit in older and medically-infermed patients. They highlight the need for randomized trials to identify which patients are the best candidates for transplant. The new effective drug combinations, including novel flit-3 inhibitors, or combinations of hypomethylating agents with venetoclax, haven't been tested yet in conjunction with transplant.